Erenumab is a monoclonal antibody indicated for the preventive treatment of migraine by blocking the activity of calcitonin gene-related peptide (CGRP); it has demonstrated superiority over placebo in migraine prevention, including in patients who have failed multiple prior standard preventive therapies, and is well tolerated.